{"id":"NCT01972841","sponsor":"Astellas Pharma Europe B.V.","briefTitle":"This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder","officialTitle":"A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multi-center Study to Evaluate the Efficacy, Safety and Tolerability of Combinations of Solifenacin Succinate and Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in the Treatment of Overactive Bladder","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-11-05","primaryCompletion":"2015-10-22","completion":"2015-10-22","firstPosted":"2013-10-31","resultsPosted":"2018-06-12","lastUpdate":"2024-10-31"},"enrollment":3527,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Urinary Bladder Overactive","Urinary Bladder Diseases\\Urologic Diseases","Overactive Bladder","Urgency Incontinence"],"interventions":[{"type":"DRUG","name":"Solifenacin succinate","otherNames":["Vesikur","Vesitrim","YM905","Vesicare"]},{"type":"DRUG","name":"Mirabegron","otherNames":["YM178","Betmiga","Betanis","Myrbetriq"]},{"type":"DRUG","name":"Placebo to match solifenacin succinate","otherNames":[]},{"type":"DRUG","name":"Placebo to match mirabegron","otherNames":[]}],"arms":[{"label":"1: Solifenacin 5 mg + Mirabegron 25 mg","type":"EXPERIMENTAL"},{"label":"2: Solifenacin 5 mg + Mirabegron 50 mg","type":"EXPERIMENTAL"},{"label":"3: Placebo","type":"PLACEBO_COMPARATOR"},{"label":"4: Solifenacin 5 mg","type":"ACTIVE_COMPARATOR"},{"label":"5:Mirabegron 25 mg","type":"ACTIVE_COMPARATOR"},{"label":"6: Mirabegron 50 mg","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study was to examine how well two medicines (solifenacin succinate and mirabegron) combined work compared to each medicine alone in the treatment of bladder problems.","primaryOutcome":{"measure":"Change From Baseline to End of Treatment (EoT) in Mean Number of Incontinence Episodes Per 24 Hours","timeFrame":"Baseline and EoT (up to 12 weeks)","effectByArm":[{"arm":"Placebo","deltaMin":-1.34,"sd":0.1},{"arm":"Mirabegron 25 mg","deltaMin":-1.7,"sd":0.1},{"arm":"Mirabegron 50 mg","deltaMin":-1.76,"sd":0.1},{"arm":"Solifenacin 5 mg","deltaMin":-1.79,"sd":0.1},{"arm":"Solifenacin 5 mg + Mirabegron 25 mg","deltaMin":-2.04,"sd":0.07},{"arm":"Solifenacin 5 mg + Mirabegron 50 mg","deltaMin":-1.98,"sd":0.07}],"pValues":[{"comp":"OG003 vs OG004","p":"0.072"},{"comp":"OG003 vs OG005","p":"0.033"},{"comp":"OG001 vs OG004","p":"0.001"},{"comp":"OG002 vs OG005","p":"0.052"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":11},"locations":{"siteCount":435,"countries":["United States","Argentina","Australia","Belgium","Bulgaria","Canada","China","Colombia","Czechia","Denmark","Estonia","Finland","France","Germany","Greece","Hong Kong","Hungary","Italy","Latvia","Lithuania","Malaysia","Mexico","Netherlands","New Zealand","Norway","Peru","Philippines","Poland","Romania","Russia","Singapore","Slovakia","Slovenia","South Africa","South Korea","Spain","Sweden","Taiwan","Thailand","Turkey (TÃ¼rkiye)","Ukraine","United Kingdom"]},"refs":{"pmids":["37160401"],"seeAlso":["https://astellasclinicalstudyresults.com/study.aspx?ID=254"]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":429},"commonTop":["Dry mouth"]}}